Complete Cytoreduction of Advanced Ovarian Malignancy using Neutral Argon Plasma. Madhuri TK , Tailor A , Butler-Manuel SA Department of Gynaecological Oncology Royal Surrey County Hospital, Guildford, UK. Introduction
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Complete Cytoreduction of Advanced Ovarian Malignancy using Neutral Argon Plasma
Madhuri TK, Tailor A, Butler-Manuel SADepartment of Gynaecological OncologyRoyal Surrey County Hospital, Guildford, UK
Ovarian cancer is 2nd common gynaecological cancer after breast and is the commonest cause of death.Management includes surgery and chemotherapy with a good initial response but women often relapse.1
Data has consistently shown that complete cytoreductive surgery improves survival. 2 (figure 1 & 2)
There has been no new technology since 2001 when the Argon Beam coagulator (ABC) was used to produce complete cytoreduction. The PlasmaJet™ (PJ) is a new surgical device releasing neutral argon plasma. Prospective, observational study performed with satisfactory results. 3
Figure 2 PJ being used to ablate tumour nodules on bowel surfaces.
Figure 3 PJ coagulating bleeding areas on bowel surfaces.
15 primary debulking procedures for advanced ovarian cancer
6 secondary debulking procedures for recurrent ovarian cancer
Pooled data from Chu et al confirms that optimal surgery is associated with increased survival. (Table 1)
Traditionally the benchmark for optimal surgery has been <1cm macroscopic residual.
Today, the aim of complete cytoreduction is to leave no macroscopic residual disease.
Evaluate the feasibility and outcome of conversion from optimal cytoreduction (</=1cm) to microscopic disease only in open and laparoscopic surgery.
Residual disease: complete cytoreduction achieved in 17 cases.
No intra op/post op complications
Safe to use as compared with other devices
Easy to use
Survival of Patients in months With Advanced Ovarian Cancer According to the Amount of Residual Tumor after Primary Cytoreduction
Plasma: a collection of high energy small particles including free atoms, ions and electrons produced by heating a gas. PJ is a new device for clinical use designed to produce a fine jet of Argon plasma by heating argon gas.
PJ used to treat peritoneal deposits of EOC metastases on serosal surface of small and large bowel in all 11/15 open cases and treat deposits on the serosal surface of the liver, diaphragm and peritoneal undersurface of the pericardium with no adverse affects in the 6 laparoscopic cases. 4/6 presented with recurrent disease >19 months following treatment. Disease on liver surface and diaphragmatic nodules resected with no visible disease.
Widely applicable to a wide variety of open and laparoscopic gynae surgery
Innovative surgical device to achieve optimal cytoreduction by ablation and destruction of tumour implants on visceral surfaces without the risk of lateral thermal spread in open or laparoscopic debulking surgery
Prospective, multicentre RCTs required to establish place in Gynaecological Oncology
Prospective study in tertiary oncology centre. PJ used in 15 laparotomies and 6 laparoscopic debulking.
Patient demographics, intra and post-operative data collected. Size/location of pre-surgical disease, procedures performed, tissue and anatomical location subjected to PJ, power settings and time taken to ablate tumour deposits recorded.
Correspondence to: [email protected]